| Trial ID: | L6211 |
| Source ID: | NCT00402909
|
| Associated Drug: |
Nateglinide
|
| Title: |
Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Nateglinide
|
| Outcome Measures: |
Primary: Change from baseline in hemoglobin (Hb)_A1c | Secondary: Change from baseline in 2-hour postprandial glucose during standardized meal test|Proportion of patients achieving American Diabetes Association ADA goal of HbA1c <7.0%|Proportion of patients achieving reduction in HbA1c of 0.5%
|
| Sponsor/Collaborators: |
Sponsor: Novartis Pharmaceuticals
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
28
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT
|
| Start Date: |
2006-11
|
| Completion Date: |
2007-08
|
| Results First Posted: |
|
| Last Update Posted: |
2017-02-24
|
| Locations: |
Novartis Pharmaceuticals, East Hanover, New Jersey, 07974, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00402909
|
